

AMENDMENTS TO THE CLAIMS

- 1. (Currently Amended)** A transdermal preparation containing 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a medically acceptable salt thereof ~~as the sole active ingredient~~, and an external preparation base.
- 2-4. (Cancelled)**
- 5. (Currently Amended)** The preparation according to ~~claim 4~~claim 1, for use as a prophylactic or therapeutic agent for preventing or treating a disorder in patients with overactive bladder, wherein the disorder is increased urinary frequency and urinary incontinence in patients with overactive bladder.
- 6. (Currently Amended)** The preparation according to claim 1, provided in the form of ~~patch~~a patch.
- 7. (Original)** The preparation according to claim 6, provided in the form of a single adhesive layer-type or a reservoir-type transdermal preparation.
- 8-10. (Cancelled)**
- 11. (Currently Amended)** ~~The~~A transdermal preparation for treating increased urinary frequency and urinary incontinence ~~according to claim 1~~, containing ~~as the sole active ingredient~~ 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a medically acceptable salt thereof, ~~and comprising~~ an external preparation base and a structural body.
- 12. (Cancelled)**

13. (Currently Amended) The transdermal preparation for treating increased urinary frequency and urinary incontinence according to claim 11, which is of a reservoir type preparation, ~~comprising:~~

~~wherein a mixture of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide as the sole active ingredient is present in a mixture with and a single or combination one or more of the~~ external preparation bases; and

~~wherein the a structural body comprising comprises~~ a membrane for controlling drug permeation, an adhesive layer, a support, and a peelable liner.

14-16. (Cancelled)

17. (New) The transdermal preparation for treating increased urinary frequency and urinary incontinence according to claim 11, which is of a single adhesive layer type preparation,

wherein 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a medically acceptable salt thereof is present in an adhesive layer containing styrene-isobutylene-styrene block copolymer and ultra-pale rosin ester as the external preparation bases; and

wherein the structural body comprises a support and a peelable liner.

18. (New) The transdermal preparation for treating increased urinary frequency and urinary incontinence according to claim 13, wherein the external preparation bases comprise hydroxypropylmethylcellulose (HPMC), and ethanol/water mixture.

19. (New) The preparation according to claim 1, wherein the transdermal preparation is provided in the form of a single adhesive layer-type transdermal preparation, and the external preparation bases comprise styrene-isobutylene-styrene block copolymer and ultra-pale rosin ester.

20. (New) The preparation according to claim 1, wherein the transdermal preparation is provided in the form of a reservoir-type transdermal preparation, and the external preparation bases comprise hydroxypropylmethylcellulose (HPMC), and ethanol/water mixture.

21. (New) A method for preventing or treating increased urinary frequency or urinary incontinence in patients with overactive bladder, comprising administering a therapeutically effective amount of the preparation according to claim 1 to the patient with the overactive bladder.

22. (New) A method for preventing or treating increased urinary frequency or urinary incontinence in patients with overactive bladder, comprising administering a therapeutically effective amount of the preparation according to claim 11 to the patient with the overactive bladder.